Jpmorgan Chase & CO Akari Therapeutics PLC Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
About Akari Therapeutics Plc
- Ticker AKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,349,200
- Market Cap $123M
- Description
- Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...